Biomea Fusion (BMEA) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic focus and leadership

• Focused on two main assets: a first-in-class beta cell restorative therapy and a next-generation GLP-1 agent.

• Leadership team is experienced with a clear vision and execution plan.

• Company has a cash runway through key upcoming inflection points.

Scientific innovation and clinical progress

• First menin inhibitor targeting diabetes, aiming to restore pancreatic beta cells rather than just lowering blood sugar.

• Preclinical and clinical data show significant C-peptide increases and beta cell mass growth in Type 1 diabetes.

• Combination of menin inhibitor with GLP-1 agonist in obesity shows muscle preservation, additional weight loss, and health benefits.

• Phase II studies in Type 1 and Type 2 diabetes are ongoing, with key readouts expected by end of next year.

Market opportunity and differentiation

• Diabetes and obesity represent large, underserved markets with current therapies only addressing symptoms.

• Menin inhibition offers a novel approach by restoring beta cell function, potentially delaying or avoiding insulin dependence.

• Next-generation GLP-1 (BMF-650) aims to improve tolerability and patient persistence compared to current GLP-1 drugs.